Calistoga Drug Shrinks Tumors in Lab Studies

Luke Timmerman12/9/08

Seattle-based Calistoga Pharmaceuticals said that its lead experimental drug, CAL-101, killed cancer cells in lab studies of multiple blood malignancies. The drug is designed to block a marker inside cells called the PI3 kinase pathway, that is thought to play a key role in tumor cell growth, survival, and migration. The findings were delivered in an oral presentation at the American Society of Hematology meeting in San Francisco.

Luke Timmerman is the National Biotech Editor of Xconomy. E-mail him at ltimmerman@xconomy.com Follow @